Repligen Corp. (RGEN)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

41 SEYON STREET WALTHAM, MA 02453

Repligen Corp. develops novel therapeutics for the treatment of diseases of the central nervous system. The company markets Protein A products which are used in the production of monoclonal antibodies, and SecreFlo, used as an aid in the diagnosis of certain pancreatic disorders.

Data as of 2021-05-08 10:44:38 -0400
Market Cap10.311 Billion Shares Outstanding54.904 Million Avg 30-day Volume296.746 Thousand
P/E Ratio129.59941 Dividend Yield EPS1.45
Price/Sales23.81 Debt to Equity1.24 EBITDA123.421 Million
Price to Book Value6.63 Forward PE83.24 Enterprise Value9.6 Billion
Total Cash711.318 Million Current Debt313.328 Million Gross Profit248.608 Million
BETA0.88127 52-week High/Low228.83 / 109.38 Next Earnings Date2021-07-29 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from RGEN instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 11 9 22.22% 7 (0.42%) 5 (0.31%) 40.0%
Funds Holding: 443 386 14.77% 116 (6.97%) 103 (6.41%) 12.62%
13F shares: 45.844 Million 44.367 Million 3.33% 13.681 Million 14.535 Million -5.88%
% Ownership 83.7839 84.3163 -0.63% 25.0032 27.6232 -9.48%
New Positions: 97 60 61.67% 27 20 35.0%
Increased Positions 154 139 10.79% 42 41 2.44%
Closed Positions 37 34 8.82% 14 11 27.27%
Reduced Positions 151 135 11.85% 37 30 23.33%
Total Calls 202.536 Thousand 325.268 Thousand -37.73% 52.2 Thousand 109.8 Thousand -52.46%
Total Puts 193.238 Thousand 93.467 Thousand 106.74% 36.1 Thousand 11.8 Thousand 205.93%
PUT/CALL Ratio 0.95 0.29 227.59% 0.69 0.11 527.27%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding RGEN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RGEN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

2 Thousand total shares from 3 transactions

Exercise Derivative Conversion (M)

15 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

DAWES KAREN A

  • Director
115,449 2021-05-11 3

BYLUND JAMES SVP, GLOBAL OPERATIONS & IT

  • Officer
6,324 2021-04-06 2

GEBSKI CHRISTINE SEE REMARKS

  • Officer
37,140 2021-03-16 2

RYAN THOMAS F JR

  • Director
1,294 2021-03-12 4

HUNT ANTHONY CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
212,762 2021-03-12 7

KURIYEL RALF SENIOR VP, R&D

  • Officer
31,176 2021-03-10 5

SNODGRES JON CHIEF FINANCIAL OFFICER

  • Officer
32,363 2021-03-04 5

BARTHELEMY NICOLAS

  • Director
1,450 2020-11-09 2

EGLINTON MANNER CARRIE

  • Director
0 2020-06-11 2

MUIR GLENN P

  • Director
5,905 2020-05-13 0

COX JOHN

  • Director
923 2020-03-24 0

MHATRE ROHIN

  • Director
0 2020-03-01 0

COOPER GLENN L MD

  • Director
35,709 2019-05-23 0

EDDLEMAN ROY T

  • 10% Owner
No longer subject to file 2018-08-09 0

BENJAMIN HOWARD VP BUSINESS DEVELOPMENT

  • Officer
33,908 2017-12-14 0

RUSCHE JAMES R SENIOR VICE PRESIDENT

  • Officer
No longer subject to file 2016-12-31 0

GOLDBERG ALFRED LEWIS

  • Director
40,331 2015-05-21 0

HERLIHY WALTER C PRESIDENT, CEO

  • Officer
  • Director
262,430 2015-05-12 0

GRIFFITH MICHAEL A

  • Director
1,932 2014-11-10 0

WITT DANIEL P SENIOR VICE PRESIDENT

  • Officer
77,999 2014-06-20 0

KELLY WILLIAM J CHIEF ACCOUNTING OFFICER

  • Officer
5,456 2014-02-27 0

HENRY EARL WEBB

  • Director
21,380 2013-05-09 0

LIEBER JONATHAN I CFO

  • Officer
15,000 2013-02-28 0

HALL MICHAEL CHIEF MEDICAL OFFICER

  • Officer
5,000 2012-03-12 0

SPURR ROBERT CHIEF COMMERCIAL. OFFICER

  • Officer
10,000 2012-03-12 0

RICH ALEXANDER

  • Director
0 2011-12-15 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

LAMPERT MARK N

BVF INC/IL

  • 10% Owner
  • INDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER
No longer subject to file 2009-07-06 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

DAWES KAREN A - Director

2021-05-13 17:01:29 -0400 2021-05-11 M 15,000 $3.22 a 115,734 direct

DAWES KAREN A - Director

2021-05-13 17:01:29 -0400 2021-05-11 M 15,000 d 0 direct

DAWES KAREN A - Director

2021-05-13 17:01:29 -0400 2021-05-11 S 285 $176.85 d 115,449 direct

BYLUND JAMES - Officer SVP, GLOBAL OPERATIONS & IT

2021-04-08 19:55:43 -0400 2021-04-06 S 360 $204.25 d 6,324 direct 0.4464 3.4934 3.6245 5 -0.393 4

GEBSKI CHRISTINE - Officer SEE REMARKS

2021-03-18 21:47:31 -0400 2021-03-16 S 1,400 $196.88 d 37,140 direct 1.6913 -10.0397 2.0197 8.3141 27 -11.579 5

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
REPLIGEN CORP RGEN 2021-05-14 22:15:03 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 21:45:03 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 21:15:03 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 20:45:03 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 20:15:04 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 19:45:02 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 19:15:03 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 18:45:03 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 18:15:03 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 17:45:03 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 17:15:03 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 16:45:03 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 16:15:03 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 15:45:03 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 15:15:02 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 14:45:04 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 14:15:03 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 13:45:03 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 13:15:03 UTC -0.2 0.25 2000000
REPLIGEN CORP RGEN 2021-05-14 12:45:03 UTC -0.2 0.25 2000000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund RGEN -8273.0 shares, $-1378033.61 2020-10-31 N-PORT
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund RGEN -1162.0 shares, $-222674.06 2020-12-31 N-PORT
AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund RGEN -20.0 shares, $-2950.8 2020-09-30 N-PORT
Jackson Variable Series Trust- JNL/Nicholas Convertible Arbitrage Fund RGEN -12255.0 shares, $-1183097.7 2020-03-31 N-PORT
AQR Funds- AQR Alternative Risk Premia Fund RGEN -605.0 shares, $-115936.15 2020-12-31 N-PORT
RUSSELL INVESTMENT CO- Sustainable Equity Fund RGEN -1838.0 shares, $-367600.0 2021-01-31 N-PORT
RUSSELL INVESTMENT CO- U.S. Dynamic Equity Fund RGEN -1191.0 shares, $-238200.0 2021-01-31 N-PORT
Nuveen Investment Trust II- Nuveen Equity Long/Short Fund RGEN -3000.0 shares, $-637170.0 2021-02-28 N-PORT

Elevate your investments